Home > Insider Trading > Filing (0001104659-19-030609)

Filing Details

Accession Number:: 0001104659-19-030609
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-05-20 18:00:41
Reporting Period:: 2019-05-16

Accepted Time:: 2019-05-20 18:00:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1740547	Urovant Sciences Ltd.	UROV	()	D0

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1635088	Ltd. Sciences Roivant	Suite 1, 3Rd Floor 11-12 St. James'S Square London X0 SW1Y 4LB		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares, Par Value $0.000037453 Per Share	Acquisiton	2019-05-16	5,408	$6.79	22,709,077	No	4	P	Direct
Common Shares, Par Value $0.000037453 Per Share	Acquisiton	2019-05-17	6,200	$7.36	22,715,277	No	4	P	Direct
Common Shares, Par Value $0.000037453 Per Share	Acquisiton	2019-05-20	8,285	$7.98	22,723,562	No	4	P	Direct
Common Shares, Par Value $0.000037453 Per Share	Acquisiton	2019-05-20	1,715	$8.39	22,725,277	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $6.70 to $6.93, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.03 to $7.85, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.35 to $8.35, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.36 to $8.47, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4.